Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41results about How to "Delay Elimination" patented technology

Substituted-pent-4-ynoic acids

InactiveUS6037367AImprove the level ofSuppressing inappropriate activationBiocideOrganic chemistryMethyl groupCarbon atom
PCT No. PCT / US96 / 11613 Sec. 371 Date Sep. 14, 1998 Sec. 102(e) Date Sep. 14, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97 / 03945 PCT Pub. Date Feb. 6, 1997Compounds of formula (I) wherein: R1 is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, (CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR6: W is alkynyl or 2 carbon atoms; R3 is H or R7; Z is C(O)R13, (CH2)0-1C(O)OR13, (CH2)0-1C(O)NR10R13, (CH2)0-1C(R8R8)OR8, -NHC(O)R7, (CH2)0-1NR10R13, NH[C(O)C(O)OR8], CH2NH[C(O)CNR10R13], CH2S(O)qR7, CH[S(O)qR7]2, dithiolane, (tetrazol-5-yl), thiazol-2-yl, [1,2,4]thiadiazol-5-yl, [1,3,4]oxadiazol-2-yl, imidazol-2-yl, oxazol-2-yl, or (3- or 5-oxadiazolyl[1,2,4]; R7 is -(CR4R5)qR11 or C1-6 alkyl wherein the R11 or C1-6 alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -NR8R10, -CO2R8, -O(CH2qR8, -NR8C(O)R8 or R12; or the pharmaceutically acceptable salts thereof.
Owner:SMITHKLINE BECKMAN CORP

Composition

Disclosed and claimed are methods for oral contraception, or a hormone replacement therapy, or for treating breast cancer, in a patient in need thereof involving administering to the patient, at a dosage of no greater than 200 mug / day per 70 kg subject, a compound having Formula (I):wherein X in combination with K form a steroidal ring and R5 is a sulphamate group that has of the formula:wherein each of R1 and R2 is H.
Owner:SCHERING AG +1

Plasma-like substance

An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed. The use of the plasma-like solution in organ transplant, novel chemotherapy procedures, and tissue, organ and organism cryopreservation are also disclosed.
Owner:LINEAGE CELL THERAPEUTICS INC

Cyclic dinucleotides for cytokine induction

A cyclic dinucleotide compound of Formula (I):wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.
Owner:KAYLA THERAPEUTICS

Antigen-binding molecule for eliminating aggregated antigens

The present inventors discovered that incorporating an Fc region and an antigen-binding domain whose antigen-binding activity varies depending on ion concentration into an antigen-binding molecule that binds to an aggregate-forming antigen produces an antigen-binding molecule that can preferentially clear protein aggregates in comparison to protein monomers from plasma. Use of antigen-binding molecules of the present invention allows various diseases stemming from target tissues to be treated target-tissue-specifically. Use of antigen-binding molecules of the present invention enables treatment of diseases caused by protein aggregates.
Owner:CHUGAI PHARMA CO LTD

Method, device and system for recording song audio

The invention discloses a method, a device and a system for recording a song audio and belongs to the technical field of computers. The method comprises steps of: sending an accompaniment audio to a Bluetooth device through an accompaniment channel and sending a time sequential value to the Bluetooth device through a data channel according to a preset period; receiving a human voice audio sent by the Bluetooth device through a human voice channel and receiving a first time sequential value sent by the Bluetooth device through the data channel, wherein the first time sequential value is the time sequential value received when the Bluetooth device begins to play the accompaniment audio; and according to a second time sequential value sent when the accompaniment audio is begun to be sent to the Bluetooth device, and the first time sequential value, carrying out audio mixing on the accompaniment audio and the received human voice audio so as to obtain the sound audio. By use of the method, the device and the system, synchronization degree of the accompaniment audio and the human voice audio can be increased.
Owner:GUANGZHOU KUGOU COMP TECH CO LTD

Novel Betulinic Acid Derivatives

The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(═CH2) CH3 or CH(CH3)2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R3 or R4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R3 and R4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R1 is zero when Y is O, and R1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells.
Owner:DABUR PHARM LTD

Switch circuit capable of quickly discharging transistor parasitic capacitance charge and charge discharging method thereof

ActiveCN102832799ATimely loadReduce load startup delay timePower conversion systemsControl signalParasitic capacitance
The invention claims a switch circuit capable of quickly discharging transistor parasitic capacitance charge. The switch circuit comprises a transistor connected with the load; the input end of the transistor is connected with a charge discharging circuit; the charge discharging circuit receives a second controlling signal provided by the external device for discharging the charge on the transistor parasitic capacitance under the action of the second controlling signal, and lowering the potential on the input end of the transistor to the reference potential. At the same time, the invention also discloses the charge discharging method of the switch circuit. The switch circuit provided by the invention can effectively eliminate the delay phenomenon when starting up the load through quickly regulating the potential on the input end of the transistor down by utilizing the charge discharging circuit in the transitional stage of turning from on to off, thus greatly reducing the time cost wasted on reducing the virtual high potential of the input end after the transistor is on.
Owner:SUZHOU YONGJIAN PHOTOELECTRIC TECH

Non-invasive detection system and method for automatic neuropathy

The invention relates to a non-invasive detection system and method for automatic neuropathy. The non-invasive detection system comprises an electrode array, a voltage reference module, a switch array, a measuring module, an adjustable resistor, a discrete voltage module, a central processing unit, an analysis module and the like. The method comprises the steps of using the adjustable precision resistor for achieving human body resistance changes and an equivalent resistance of a capacitance effect after a human body resistance and the equivalent resistance of the capacitance effect; then, determining an access to be tested; after voltages of two poles of an electrode and the voltage of the adjustable precision resistor in a circuit are tested and stored, processing data to generate I-U curve charts so as to obtain a group of slope data; and performing automatic neuropathy feature analysis through comparison of a pathology database according to the slope data to obtain the pathology condition to which a subject belongs, and outputting results.
Owner:上海中嘉衡泰医疗科技有限公司

Kit for caring for a fabric article

InactiveUS7531493B2Easy to useImproved care resultSoftening compositionsLiquid soapsTrade dressBiomedical engineering
A kit for caring for a fabric article includes multiple products such as a fabric treatment composition and a laundry detergent composition, a fabric conditioning composition, and / or a second fabric treatment composition. Each of the multiple products contains a coordinated element, such as a brand name, a characteristic ingredient, container graphics, containers, dosages per container, a dye, a perfume, a trade dress, a set of usage instructions, and a combination thereof.
Owner:THE PROCTER & GAMBLE COMPANY

Multifunctional image processor

An image processor used in digital camera unit, includes a LCD interface connected with LCD module, the image processor can implement controlling the LCD module and data transmitting with LCD module through this LCD interface. The channel formed between LCD interface and host interface of connecting module of host machine is a transparent channel, the host machine module is connected with LCD module ; the said image processor also includes a independent MCU (micro control unit), when this image processor is used in a independent digital camera, this MCU can be a replacement of main control unit in host machine. It also can used in the mobile communication terminal with video capture, and no need to take a big change.
Owner:VIMICRO CORP

Mobile communication terminal device with pickup head

The device comprises at least a picking up module, baseband module, and LCD module. The baseband module does not connect to the LCD module directly. The baseband module through the picking up module controls operation of LCD module. The picking up module provides a transparent bridge between the baseband module and the LCD module. Image and data are transferred between LCD module of the picking up module and the LCD module. Comparing with prior art, advantages of the invention are: delay phenomenon between displayed image and actual frame is better eliminated since the picking up module and LCD module is connected directly. Thus, user can capture any watched suitable image.
Owner:VIMICRO CORP

Pivoting high flux x-ray target and assembly

InactiveUS20100284518A1Improved heat managementAccelerated dissipationX-ray tube electrodesTarget surfaceHigh flux
A high flux X-ray tube anode target assembly (101). The assembly includes a support shaft (107) connected to a pivot assembly (109). The assembly further includes a movable anode target (105) having a target surface (106) disposed at one end of the support shaft. The target surface includes a single radius of curvature. The radius of curvature extends from a pivot point (110). The assembly also includes a drive member (119) operably arranged with respect to the support shaft to provide motion to the anode target. The assembly is configured to maintain a substantially fixed distance between the pivot point and the target surface.
Owner:GENERAL ELECTRIC CO

Transient control drive method and circuit, and image display system thereof

The present invention relates to a transient control drive method, for driving a liquid crystal capacitor of a pixel circuit from a first voltage level to a second voltage level, comprises: driving the liquid crystal capacitor from the first voltage level to an intermediate voltage level; and driving the liquid crystal capacitor from the intermediate voltage level to the second voltage level. The present invention further provides a transient control drive circuit and an image display system thereof.
Owner:INNOLUX CORP

Metal complex-containing pharmaceutical agents

Improved metal complex-containing pharmaceutical agents are described which, as an additive, contain one or more complexing agents and / or one or more weak metal complex(es) or mixtures thereof.
Owner:GRIES HEINZ +4

Moving high flux x-ray target and assembly

An X-ray tube anode target assembly (101) having a support shaft (107) connected to a pivot assembly (109) and a movable anode target (105) having a target surface (106) disposed at one end of the support shaft and a contact element (108) disposed at the opposite end of the support shaft. A first drive assembly (115) is operably arranged with respect to the support shaft to provide oscillatory motion to the anode target about a first axis substantially parallel to the support shaft and a drive cylinder (125) is operably arranged with respect to the contact element to provide a pivoting motion to the support shaft. A second drive assembly (127) is operably arranged with respect to the drive cylinder to provide an oscillatory motion to the drive cylinder, the second drive cylinder being further configured to provide a linear motion parallel to the first axis. The target surface is maintained at a substantially constant angle of impingement and maintains a substantially fixed distance from a cathode (103) during target motion.
Owner:GENERAL ELECTRIC CO

Manufacturing and engineering of DNASE enzymes for therapy

The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and / or release. In accordance with the invention, the DNase variant has advantages for therapy and / or large-scale manufacturing.
Owner:NEUTROLIS INC

Diverter valve integrated with waterway switch, waterway control method and cleaning waterway

The invention discloses a diverter valve integrated with a waterway switch, a waterway control method and a cleaning waterway. The diverter valve comprises a valve element, a valve seat and a rotary driving part, a plurality of water outlets communicated with water use channels are formed in the end face, making contact with the valve element, of the valve seat, water passing holes communicated with a water inlet are formed in the end face, making contact with the valve seat, of the valve element, and the rotary driving part drives the valve element to rotate relative to the valve seat; and the water outlets and the water passing holes are distributed in a circular ring with the relative rotation center as the circle center, a blocking piece used for blocking the water inlet when the valve element rotates to the set position where the water passing holes and the water outlets are not communicated is further included, and the blocking piece and the valve element rotate synchronously. The diverter valve has the advantages of being simple in structure, flexible and convenient to adjust, integrated in function and the like; the waterway control method has the advantages of being high in adjusting sensitivity, eliminating the delay phenomenon, optimizing the use feeling of a user and the like; and the cleaning waterway has the advantages of being high in stability, obvious in cost optimization and the like.
Owner:湖南麦格米特电气技术有限公司

Manufacturing and engineering of dnase enzymes for therapy

The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and / or release. In accordance with the invention, the DNase variant has advantages for therapy and / or large-scale manufacturing.
Owner:NEUTROLIS INC

Control method for multi-power source powertrain for vehicle

The invention discloses a control method of a multi-power source power assembly for a vehicle. The power requirement of the whole vehicle is decomposed into five levels of control such as working condition, mode, gear, power distribution and power source. Firstly, the vehicle operating data such as whole vehicle speed, the electrical charge state of a power battery, the state of an accelerator pedal and the time rate of change thereof, the state of a brake pedal and the time rate of change thereof are collected in real time through a power assembly controller when an electric vehicle runs; then, the power assembly controller realizes the power distribution and control for each power source of the power assembly through the five levels in sequence; the first to fourth levels of control in the five levels of control are used for selecting corresponding optimal working points according to stored data respectively, complicated calculation is not needed, the calculated amount of the control method is greatly reduced, the delay phenomenon caused by complicated mathematical formula calculation is eliminated, the requirement of a hardware system is greatly reduced, the cost of the hardware system is reduced, and the energy utilization rate of the whole vehicle is greatly improved.
Owner:安徽易佳斯动力科技有限公司

Calculation Method of Correlation Coefficient of Aeroengine Load Spectrum Based on Rainflow Counting Cycle

The invention discloses an aero-engine load spectrum correlation coefficient calculating method based on rain flow counting circulation. Load spectrums of all parameters on different flight profiles are counted based on a rain flow counting method; after load circulation with the amplitude smaller than the amplitude threshold is filtered out, the circulation numbers of all the parameters of all the profiles are obtained, the different circulation numbers are obtained for different parameter load spectrums on the same flight profile, the circulation numbers, counted on all the profiles, of different parameters correspond one to one, a series of circulation data can be obtained for each load parameter, and then a correlation coefficient between all the parameters of the load spectrums are calculated. The delay phenomenon between rotation speed and overload value of an engine is eliminated, and the result more conforms to the reality. The correlation coefficient between the normal overload value representing maneuvering circulation and the rotation speed representing pneumatic circulation is close to 1 to a large extent. A basis is further provided for prediction and evaluation of aero-engine service life.
Owner:NANJING UNIV OF AERONAUTICS & ASTRONAUTICS

Moving high flux X-ray target and assembly

An X-ray tube anode target assembly having a support shaft connected to a pivot assembly and a movable anode target surface disposed at one end of the support shaft. A first drive assembly is operably arranged with respect to the support shaft to provide oscillatory motion to the anode target about a first axis substantially parallel to the support shaft and drive cylinder operably arranged with respect to the contact element to provide a pivoting motion to the support shaft. A second drive assembly is operably arranged with respect to the drive cylinder to provide an oscillatory motion to the drive cylinder, the second drive cylinder having a cam portion to provide linear motion to the support shaft parallel to the first axis. The target surface is maintained at a substantially constant angle of impingement and maintains a substantially fixed distance from a cathode during target motion.
Owner:GENERAL ELECTRIC CO

Pharmaceutical compositions

The invention relates to aqueous solution pharmaceutical compositions comprising at least one non-ionic tonicity agent, at least one buffer and an active ingredient, wherein said active ingredient is a compound of formula I, wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.
Owner:KALVISTA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products